AstraZeneca has reported that Lynparza (olaparib) in combination with abiraterone succeeded in a phase II trial by delaying disease progression in metastatic castration-resistant prostate cancer (mCRPC) patients.
More From BioPortfolio on "AstraZeneca says Lynparza/abiraterone combo delayed disease progression in mCRPC"